shown to be effective in a financial scenario as well as in clinical terms?
The most recent guidelines for ROP screening from the Royal College of Ophthalmologists and the British Association of Perinatal Medicine3 include the following inclusion criteria: any baby :;;;: 1500 g birthweight (BW) or :;;;: 31 weeks gestational age (GA). Screening programmes are designed to ensure that no baby with severe disease remains unidenti fied. This is balanced against the importance of keeping the workload to a minimum by targeting only the population at risk. To this end we have undertaken a retrospective study of ROP screening in Birmingham to assess whether the current guide lines are appropriate or include many babies who are not at risk of developing severe disease. The specific aim of this study was to determine which babies are at risk of severe disease, which we defined as any stage III. We chose this end point for two reasons: first, there is a distinct possibility that the threshold for treatment will be modified in the near future to include milder degrees of stage III ROP. Second, as babies with stage III ROP have a high risk of ophthalmic sequelae they require periodic review. 4,5
PATIENTS AND METHODS
A retrospective analysis of ROP screening records between November 1989 and November 1995 was undertaken. The notes from all six neonatal intensive care units in Birmingham were reviewed. The following data was collected: BW, GA, incidence of stage III ROP, and whether treatment was employed. All babies with a BW :;;;: 1700 g, or :;;;: 32 weeks GA were included in this screening pro gramme. Examinations, by a single observer (A.R.F.), were performed mainly on a weekly basis, although sometimes fortnightly, commenced at 3 weeks postnatal age and continued if normal until vascularisation had reached zone 3. Those with ROP were reviewed as clinically indicated. Pupil dilatation was achieved using 0.5 % cyclopentolate and 2.5% phenylephrine eye drops instilled once at least 30 minutes before examination. Indirect ophthalmoscopy was performed using a 28 dioptre lens and lid speculum after application of topical anaesthetic (0.4% oxybuprocaine). A scleral inden tor was routinely used for ocular rotation rather than indentation. 312, range 465-3080 g). The BW distribution is shown in Fig. 1 ; no baby >1200 g developed stage III ROP. GA data were available in 1423 (99.6%). The mean GA was 29.1 weeks (SD ± 2.1, range 24-38 weeks). The distribution of GA is shown in Fig. 2 
DISCUSSION
The population presented here is particularly suit able for scrutinising the criteria for ROP screening. First, the Birmingham criteria included babies who were larger and more mature than recommended by the current guidelines? Second, while not as rigorous as a previous epidemiological study, 9 and 1995 serves to highlight that even now there are significant differences between centres; indeed the incidence of severe disease is much less than in another study undertaken by the same observer in a different population. 9 Several factors contribute to this variability, including neonatal survival, standard of care and ethnic mix. While it is recognised that diagnoses by individual clinicians can vary, ZO this is less likely for severe disease than mild ROP. Our data show that stage III babies requiring treatment were less mature than those who did not, but the differences in GA of 0.4 weeks and BW of 63 g are not significant in clinical practice terms.
The current indication for treatment is 'threshold' disease -stage III ROP extending over at least 5 continuous clock-hours, or for at least 8 cumulative clock-hours -at which stage the risk of blindness is around 50%.1 Although treatment of threshold ROP has been shown to reduce unfavourable outcome (vision worse than 6/60) from 50.6% to 31.9% in zone 2 disease at 1 year, Z l at 3Yz years the difference was 57.5% compared with 46.6%,zz At 5Yz years, while fewer treated than control eyes were blind (31.5% vs 48.0%) slightly more control than treated eyes (17 % vs 13 %) had normal vision (6/12 or better)?3 The results for zone 1 disease are even less encouraging?l Thus, while the value of treatmentbe it cryotherapy or laser -is proven in severe ROP, the outcome still falls short of the ideal. Conse quently the sense of delaying treatment until there is a 50% risk of blindness must be questioned. Of course, this must be balanced against the risk of treating babies who would anyway undergo sponta neous resolution? 4 Several studies have identified severe ROP in babies born outside the :;:; 1250 g BW criterion which was used for the CRYO-ROP Study.l,16,1 9 ,3 0 ,35,36 Thus in Edinburgh1 9 1 of 47, East Midlands 9 2 of 27 and the London studl6 2 of 35, were born heavier than 1250 g but had GAs:;:; 29 weeks. If GA :;:; 29 weeks alone were considered as the single inclusion criterion, three studies identified babies with stage III disease born after 29 weeks but with BW :;:;1250 g: 1 of 47 from the Edinburgh study,1 9 2 of 27 from the East Midlands15 and 1 of 9 from New Zealand.1 4 In our study, 2 of 39 stage III babies would have fallen outside a single inclusion criterion of either:;:; 1250 g BW or :;:; 29 weeks GA (1375 g/ 29 weeks and 31 weeks/930 g respectively), although both would have been identified using BW and GA criteria together. We have attempted to determine whether any baby in these publications would have remained unidentified if BW and GA were com bined. While this was not possible in each article, in an Australian study,35 two babies with stage III would have been missed (1290 g and 33 weeks, 1435 g and 32 weeks), and in Denmark3 0 blindness developed in 16 >1250 g BW and 6 �31 weeks GA (ROP grading not provided). So far we have concentrated on the routine screening of preterm populations meeting the inclusion criteria of a R. R. GOBLE ET AL. particular screening protocol. However, it is possible that there are certain babies, some of who may fall outside the criteria, who are particularly susceptible to developing severe ROP. One such high-risk group might be babies suffering severe ischaemic neurolo gical insults. It is pertinent to note that an association between severe ROP and periventricular leucomala cia has been reported37 in 6 babies of which one was GA 30 weeks and BW 1440 g. Recently, 3 babies of 32-33 weeks GA but >2000 g BW who experienced severe prenatal blood loss and subsequently under went surgery with general anaesthesia developed ROP reaching stage III in 2, with one requiring cryotherapy.38 Clearly it would be inappropriate to widen the screening criteria to include all babies of BW >2000 g. This would increase the workload several-fold with little clinical benefit. However, such cases are important, because common aetiolo gical factors may emerge -such as severe neurolo gical injury or perinatal blood loss -which might identify babies falling outside the criteria and who require screening. To screen these additional at-risk babies would not pose a major additional workload.
Keith and Doyle35 predicted that the inclusion of GA, in addition to BW, as a criterion for screening would substantially increase workload. This expecta tion has not been realised; on the contrary, the combination of BW and GA would signficantly reduce the number of babies requiring screening.
It was particularly interesting to show how an alteration of the inclusion criteria might have enabled detection of all stage III babies whilst eliminating babies not requiring screening. Indeed, the effect of changing the inclusion criteria to :;:; 1250 g BW or :;:; 29 weeks GA would, in this study, have reduced the number of babies requiring screening by 30% (432) of 1429, and even more examinations. In the East Midlands study,15 54% fewer babies would have required screening, although the sole inclusion criterion was :;:; 1700 g BW. It is not appropriate to attempt to alter national screening guidelines on the strength of a single study, because, as shown above, there are significant differences in the incidence of severe disease between neonatal populations. Furthermore, a few babies have developed severe ROP who fell outside these criteria. To achieve clinical effectiveness, periodic review of existing guidelines should be undertaken. The estimated UK population of infants born weighing <1500 g each year is around 6600, with the proportion of survivors increasing?2 This figure does not take into account those born >1500 g but <32 weeks GA, which represented 224 babies (16%) of this study. Nevertheless, nationally, introducing new inclusion criteria could save 2300 babies annually from an ophthalmic examination. Evidence does not support the recent proposal for the exploration of screening examinations to be under taken by professions other than ophthalmologists, for babies of >1500 g BW. 3 9 We concur with Bancalari 40 that these larger babies need not be screened at all and efforts should be directed to an appropriate examination of smaller babies.
If other UK centres confirm our finding that few stage III babies are likely to be missed using revised criteria of � 1250 g BW or � 29 weeks GA, then it would seem appropriate to reconsider guidelines for ROP screening. However, it is important that the clinical events placing larger babies at risk are identified (e.g. severe neurological insult or blood loss) so that clinical guidelines can be fine-tuned accordingly, ensuring efficient practice yet without inappropriately increasing the screening load.
